CStone Pharmaceuticals (CSPHF PINK) stock market data APIs
$0.5204
0(0%)
as of June 30, 2025
Try our APIs with
free plan!
CStone Pharmaceuticals Financial Data Overview
Price chart is built with
Anychart
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in China and internationally. The company offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, a RET inhibitor for the treatment of adults with metastatic RET fusion-positive and RET-mutant medullary thyroid cancer; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. Its product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma. The company's products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for solid tumors; CS5001 for solid tumors and hematologic malignancies; and CS2013 and CS2015, a bispecific molecule for autoimmune diseases. The company was incorporated in 2015 and is headquartered in Suzhou, China.
Prev. Close
0.5204
Open
0.5204
High
0.5204
Low
0.5204
52 wk Range
0.114-0.518
Market Cap
453 M
Shares Outstanding
1 357 M
Revenue
407 M
EPS
-0.0519
Beta
0.14
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CStone Pharmaceuticals data using free add-ons & libraries
Get CStone Pharmaceuticals Fundamental Data
CStone Pharmaceuticals Fundamental data includes:
- Net Revenue: 407 M
- EBITDA: -82 060 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CStone Pharmaceuticals News
New
CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore
The deal enables CStone to prioritize its resources to focus on the development of first-in-class and best-in-class therapies with global rights. The deal enables Servier to potentially bring additio...
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma
Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy for unresectable locally advanced, recurrent or metast...
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China
CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainland China. CStone to retain the rights to no...
CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication
Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL) indication. This marks sugemalimab's third indicatio...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
